The DSC2 Knockout SK-HEP-1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DSC2 gene in the SK-HEP-1 human liver adenocarcinoma cell line. This loss-of-function model impairs desmocollin 2, a key desmosomal cadherin responsible for calcium-dependent cell-cell adhesion. The polyclonal format preserves genetic diversity across the knockout pool, making it suitable for robust functional assays without the need for clonal selection or expansion.
SK-HEP-1 cells are an epithelial-like line derived from ascitic fluid of a liver adenocarcinoma patient, and they co-express endothelial and epithelial markers. This unique background enables investigation of tumor cell plasticity and hepatocellular carcinoma progression. The cell line is widely used in cancer biology for studying adhesion, migration, and signaling in a hepatic tumor context. The line’s co-expression of endothelial markers along with epithelial characteristics reflects a transdifferentiation potential, making it a valuable system for studying tumor microenvironment interactions.
DSC2 encodes a calcium-dependent cadherin integral to desmosome assembly, interacting with plakoglobin (JUP), plakophilin (PKP2), desmoplakin (DSP), and cytokeratins to anchor intermediate filaments. Its function is modulated by upstream Wnt/??-catenin, TGF-??, and p63 pathways. Knockout disrupts desmosomal adhesion, impacting downstream targets JUP, DSP, keratin filaments, and EMT transcription factors SNAI1 and TWIST. The resulting loss of adhesion is predicted to promote Wnt signaling alterations and epithelial-mesenchymal transition, affecting pathway components such as ??-catenin and keratin 18.
In SK-HEP-1 cells, DSC2 knockout facilitates the study of desmosome-dependent adhesion in liver adenocarcinoma and its role in EMT and metastasis. The loss of DSC2 may enhance migratory and invasive phenotypes, offering a platform to test adhesion-targeted therapies. The polyclonal knockout population minimizes clonal artifacts and models heterogeneous responses, suitable for high-content phenotypic screening and drug discovery. This model can be combined with chemotherapeutics or biologics to evaluate response in the context of compromised adhesion.
Common experimental uses include Western blotting and immunofluorescence for DSC2 and desmosomal proteins, migration/invasion assays (scratch wound, Transwell), cell adhesion assays, and RT-qPCR for EMT markers (CDH1, VIM). Co-immunoprecipitation of DSC2 complexes and Wnt reporter assays (TOP/FOP) further elucidate signaling changes. These applications support research into liver cancer progression, metastasis, and desmosome-targeted interventions. Standard protocols for these assays are well-established, ensuring reproducibility. For further technical information, contact Ascent Research.
